Skip to main content
Clinical Trials/ISRCTN23677189
ISRCTN23677189CompletedNot Applicable

A study on the training response of combined strength and endurance training in insulin dependent type 2 diabetic subjects with co-morbidity

niversity Maastricht (UM) (Netherlands)0 sites36 target enrollmentStarted: March 16, 2010Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
36

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
Male

Inclusion Criteria

  • •Group A: long-term type 2 diabetes group (intervention group):
  • •2. Diagnosed with type 2 diabetes greater than 5 years according to World Health Organization (WHO) criteria
  • •3. Exogenous insulin use greater than 2 years
  • •4. Clinical signs of diabetic polyneuropathy and/or other diabetes-related
  • •5. Aged 45 - 70 years
  • •6. Body mass index (BMI) 26 - 42 kg/m^2
  • •7. Sedentary behaviour
  • •8. Agreement to volunteer for the study by giving a written informed consent
  • •Group B: intermediate hyperglycaemia group/early-diagnosed type 2 diabetes patients:
  • •2. Intermediate hyperglycemia according to WHO criteria
  • •3. HbA1c less than or equal to 6.0%
  • •4. Aged 45 - 70 years (matched with group A)
  • •5. BMI 26 - 42 kg/m^2 (matched with group A)
  • •6. Wmax (cycle ergometer): 100 - 220 Watt
  • •7. Sedentary behaviour
  • •8. Agreement to volunteer for the study by giving a written informed consent
  • •Group C: overweight/obese but otherwise healthy subjects with normal glucose tolerance:
  • •2. Normal glucose tolerance according to WHO criteria
  • •3. HbA1c less than or equal to 6.0%
  • •4. Aged 45 - 70 years
  • •5. BMI 26 - 42 kg/m^2 (matched with group A)
  • •6. Wmax: 100 - 220 Watt
  • •7. Sedentary behaviour
  • •8. Agreement to volunteer for the study by giving a written informed consent

Exclusion Criteria

  • •1. Unable to participate in a structured exercise intervention for 12 months
  • •2. Use of thiazolidinions
  • •3. Use of beta-blocker therapy less than 6 months
  • •Group B and C:
  • •1. Family history of type 2 diabetes
  • •2. Use of beta-blocker therapy
  • •3. History/clinical signs of cardiovascular and/or peripheral arterial disease

Investigators

Sponsor
niversity Maastricht (UM) (Netherlands)

Similar Trials